A first-in-class gene-regulating therapy cut seizures by up to 91% in children with Dravet syndrome in extension studies, ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...
A graduate of the University of Ibadan inspires many as she shares what she did in 300‑level that made her finish from the ...
A University of Ibadan law graduate celebrated earning a first-class degree despite not initially being interested. She shared her passion for sports law.
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...
Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed ...
The drugs have names that sound like small planets: semaglutide, liraglutide, lixisenatide. Collectively, they belong to a class of glucagon-like peptide 1 (GLP-1) analogs that has reshaped the ...
Despite being confident about his preparation, Anirudh did not anticipate securing a top 3 rank. That is why seeing AIR 2 ...
What happens when you focus on the things that truly matter and strip away the things that don’t?” the president said.
MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...